Varicella zoster virus the ACIP recommended a second dose of vaccine before school entry to ensure the maintenance of high levels of varicella immunity. In 2006, the United States Food and Drug Administration approved Zostavax for the prevention of shingles. Zostavax is a more concentrated formulation of the Varivax vaccine, designed to elicit an immune response in older adults whose immunity to VZV wanes with advancing age. A systematic review by the Cochrane Library shows that Zostavax reduces the incidence of shingles by almost 50%. Shingrix is a "V. zoster" vaccine developed by GlaxoSmithKline which was approved in the United States by the
Center for Scientific and Technical Creativity of the Youth Center for Scientific and Technical Creativity of the Youth Centers for Scientific and Technical Creativity of the Youth , NTTM) were established in the late Soviet Union during "perestroika" as enterprises whose goal was commercialization of science and technology. Other translations of the Russian term are Scientific and Technical Creativity of Youth Center, Youth Center for Scientific Creativity, etc. The Centers were introduced by a joint decree of the USSR Council of Ministers, All-Union Central Council of Trade Unions, and Komsomol Central Committee no. 321 (March 13, 1987) "об образовании единой общегосударственной системы научно-технического творчества молодежи". They were established as